Citation tools
"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort." Journal of Nuclear Medicine
62.10
(2021):
1440-1446.
Web. 22 Mar. 2025.